Used Physicians' Cancer Chemotherapy Drug Manual for Android?


Physicians' Cancer Chemotherapy Drug Manual Analysis

AI Assisted Content ·

Not written by CNET Staff.

Physicians' Cancer Chemotherapy Drug Manual is a free Android application designed for healthcare professionals and students. It provides a detailed reference for various chemotherapy drugs used in cancer treatment, offering essential information such as dosage, side effects, and administration guidelines. The app aims to facilitate informed decision-making in clinical settings, enhancing the efficiency of cancer care.

The user-friendly interface allows for quick access to drug information, making it a valuable resource for on-the-go learning or reference. Features include search functionality, drug classification, and updates on the latest treatment protocols. By consolidating critical data into one application, this manual serves as an indispensable tool for those involved in oncology, ensuring that users are well-equipped with the knowledge required for effective patient management.

Enlarged image for Physicians' Cancer Chemot…
Physicians' Cancer Chemotherapy Drug Manual 0/4

Used Physicians' Cancer Chemotherapy Drug Manual for Android?


Explore More


Full Specifications

GENERAL
Release
Latest update
Version
1.0.2.53
OPERATING SYSTEMS
Platform
Android
Additional Requirements
None
POPULARITY
Total Downloads
50
Downloads Last Week
0

Report Software

Program available in other languages


Last Updated


Developer’s Description

Completely revised and updated, the Physicians' Cancer Chemotherapy Drug Manual is an up-to-date guide to the latest information on standard...

Completely revised and updated, the Physicians' Cancer Chemotherapy Drug Manual is an up-to-date guide to the latest information on standard therapy and recent advances in the field. Written by world-class experts in clinical cancer therapeutics, this essential reference provides a complete, easy-to-use catalogue of over 100 drugs and commonly used drug regimens--both on- and off-label--for the treatment of all the major cancers.

Feature and Benefits

- Addition of 10 new agents approved by the FDA within the past year and updates to new indications for several previously approved agents

- Indications, drug doses and schedules, toxicities, and special considerations for each agent expanded and revised

- A specific chapter focused on antiemetic treatment regimens for both acute and delayed nausea/vomiting

- Diagrams of drug structures and pathways for many of the agents

- A comprehensive discussion of clinical pharmacology, special considerations, indications, and dosages

- Covers toxicity and drug-drug interactions

- A section on chemotherapy regimens for all major cancers

- Provides an overview of the basic principles of cancer drug therapy.

Subscriptions are $9.99 for one year. Your subscription will auto-renew annually at the end of each year-long term, unless cancelled. Payment will be charged to your iTunes Account at confirmation of purchase. The subscription automatically renews unless auto-renew is turned off at least 24-hours before the end of the current period. Your account will be charged $9.99 for renewal within 24-hours prior to the end of the current period. Subscriptions may be managed and auto-renewal may be turned off by going to "Play Store app > Menu > Subscriptions" after purchase. No cancellation of the current subscription is allowed during active subscription period. Any unused portion of a free trial period, if offered, will be forfeited when the user purchases a subscription to that publication. Please see the links to our privacy policy and terms of service below.

Privacy Policy - http://www.jblearning.com/privacy/

Terms of Use - http://www.jblearning.com/use/

Print Book - http://www.jblearning.com/catalog/9781284144963/


Download.com
Your review for Physicians' Cancer Chemotherapy Drug Manual
Download.com

AI Assisted Content Disclosure

Content created and reviewed by Softonic with information obtained from Atmosphere_Apps, using AI.

CNET's editorial team was not involved in the creation of this content. Opinions, analysis and reviews were not provided by CNET.